#	Pagina
attuale pagina	/open-h2020/projects/195641/index.html
-1	/open-h2020/per-topic/freeing/list/index.html
-2	/open-h2020/projects/210843/index.html
-3	/open-h2020/projects/207392/index.html

Opendata, web and dolomites

ImmunoFarm

IgA-based oral therapy for protection of piglets against infection with enterotoxigenic E. coli.

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

ImmunoFarm project word cloud

Explore the words cloud of the ImmunoFarm project. It provides you a very rough idea of what is the project "ImmunoFarm" about.

effect cocktails first f18 bulk resistance assays prophylaxis twenty enterotoxigenic biosafe illness formulations fight immunity world negative receiving losses mucosal seed display vivo coli transformants predominantly pigs synergistic benthamiana anti maternal postweaning scalable prolong performed phage additive regular lactogenic transient soya responsible except domains feed seeds pig vitro industry global expression villus arabidopsis format caused transferred formulation antibiotics post treatment obtain pwd weaning infections group oligoclonal surfaces neutralisation platform host antibodies economic rest rearing thaliana prophylactic antibody strategy nicotiana elite engineered etec f4 groups strains abundance fimbriae genes immunotherapy diarrhoea agent vhhs adhesion forbidden piglets passive siga

Project "ImmunoFarm" data sheet

The following table provides information about the project.

Coordinator	VIB Organization address address: RIJVISSCHESTRAAT 120 city: ZWIJNAARDE - GENT postcode: 9052 website: www.vib.be contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Belgium [BE]
Project website	https://www.facebook.com/ImmunoFarm-356855711413541/
Total cost	160˙800 €
EC max contribution	160˙800 € (100%)
Programme	1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
Code Call	H2020-MSCA-IF-2014
Funding Scheme	MSCA-IF-EF-ST
Starting year	2015
Duration (year-month-day)	from 2015-05-01 to 2017-08-13

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	VIB VIB Organization address address: RIJVISSCHESTRAAT 120 city: ZWIJNAARDE - GENT postcode: 9052 website: www.vib.be contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	BE (ZWIJNAARDE - GENT)	coordinator	160˙800.00

Map

Project objective

Postweaning diarrhoea (PWD) in pigs is responsible for important economic losses in the global pig rearing industry. This illness is predominantly caused by enterotoxigenic E. coli strains carrying the F4 (ETEC-F4) and F18 (ETEC-F18) fimbriae. There is no treatment available to fight PWD except using antibiotics. However, the prophylactic use of antibiotics is forbidden in Europe and is expected to become forbidden in the rest of the world because of increasing abundance of resistance genes. Delivery of sIgA to mucosal surfaces as passive immunotherapy agent is a very promising strategy to prolong maternal lactogenic immunity against post-weaning infections. The aim of this project is to produce sIgA-like anti-ETEC antibodies in a cost-effective platform. Twenty different anti ETEC-F18 antibodies in a sIgA-like format will be engineered from phage display-selected variable domains (VHHs) currently available in the host institute. The synergistic or additive neutralisation effect of oligoclonal antibody cocktails will be evaluated using ETEC-F18 in vitro villus adhesion assays. The different antibodies will be produced first by transient expression in Nicotiana benthamiana and second in seeds of Arabidopsis thaliana transformants. An in vivo ETEC-F18 challenge will then be performed using two groups of piglets, one receiving the most effective seed-derived feed formulations and the other one receiving regular feed (negative control group). The sIgA antibodies of the elite oligoclonal formulation will then be transferred to biosafe soya seeds as production platform. These steps will lead towards the development of scalable procedures to obtain a cost effective bulk production of a feed based prophylaxis against ETEC.

Publications

List of publications.
year	authors and title	journal	last update
2016	Vikram Virdi, Paloma Juarez, Veronique Boudolf, Ann Depicker Recombinant IgA production for mucosal passive immunization, advancing beyond the hurdles published pages: 535-545, ISSN: 1420-682X, DOI: 10.1007/s00018-015-2074-0	Cellular and Molecular Life Sciences 73/3	2019-07-24
2016	Paloma Juarez, Vikram Virdi, Ann Depicker, Diego Orzaez Biomanufacturing of protective antibodies and other therapeutics in edible plant tissues for oral applications published pages: n/a-n/a, ISSN: 1467-7644, DOI: 10.1111/pbi.12541	Plant Biotechnology Journal	2019-07-24

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "IMMUNOFARM" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "IMMUNOFARM" are provided by the European Opendata Portal: CORDIS opendata.